Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 17/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8459482 | 1.00 | OPRK1 (1.00) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL10434997 | 0.93 | OPRK1 (0.86) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL10434613 | 0.90 | OPRK1 (0.82) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL5630305 | 0.90 | OPRK1 (0.82) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL7985237 | 0.88 | OPRK1 (0.78) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL6479796 | 0.88 | OPRK1 (0.78) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL6479790 | 0.88 | OPRK1 (0.78) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL5629630 | 0.87 | OPRK1 (0.77) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL10434844 | 0.87 | OPRK1 (0.76) | OPRK1CYP2D6CYP3A4TSHRCYP2C19 | |
| SCHEMBL6360245 | 0.86 | OPRK1 (0.75) | OPRK1CYP2D6OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960612-B2 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 2005-11-01 | — | — | US | claimed |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2004-11-04 | — | — | US | claimed |
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | KRUSE LAWRENCE I (US) | 2003-12-25 | — | — | US | claimed |
| US-RE38133-E1 | N-Arylalkylenecarbonyl-N-methyl-benzylamine derivatives; analgesics, opioid agonists, antiinflammatory agents | ADOLOR CORPORATION | 2003-06-03 | — | — | US | claimed |
| US-20020042399-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-04-11 | — | — | US | claimed |
| JP-2001510154-A | — | — | 2001-07-31 | — | — | JP | claimed |
| EP-0998281-A1 | KAPPA AGONIST COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND METHOD OF PREVENTION AND TREATMENT OF PRURITUS THEREWITH | Adolor Corporation (US) | 2000-05-10 | — | — | EP | claimed |
| US-6028063-A | ADMINISTERING COMPOUND WITH OPIOID ACTIVITY | ADOLOR CORPORATION (US) | 2000-02-22 | — | — | US | claimed |
| WO-1999003468-A1 | KAPPA AGONIST COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND METHOD OF PREVENTION AND TREATMENT OF PRURITUS THEREWITH | ADOLOR CORPORATION (US) | 1999-01-28 | — | — | WO | claimed |
| US-7294647-B2 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| US-6960612-B2 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-6028063-A | ADMINISTERING COMPOUND WITH OPIOID ACTIVITY | ADOLOR CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| US-5945443-A | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1999003468-A1 | KAPPA AGONIST COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND METHOD OF PREVENTION AND TREATMENT OF PRURITUS THEREWITH | ADOLOR CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
| US-5763445-A | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 1998-06-09 | — | — | US | disclosed |
| US-5744458-A | ANALGESICS | ADOLOR CORPORATION (US) | 1998-04-28 | — | — | US | disclosed |
| US-5688955-A | ANALGESICS | ADOLOR CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 946/4885CYP3A4 798/4885 |
| US-20020042399-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 843/4885CYP3A4 695/4885 |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 886/4885CYP3A4 737/4885 |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 541/4885CYP3A4 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.